Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus

Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus

“…Triamcinolone acetonide dental paste has been reported to give satisfactory treatment outcomes in patients with OLP in a few studies. 29 In this study, both drugs resulted in reduction of painful symptoms, lesion size, and severity, and improved patient's quality of life during a 2-month period. The difference of these scores between groups was not statistically significant at the end of treatment period.…”

“…Although it is more popular than cream-/ ointment-based forms for OLP, many patients are uncomfortable with its sticky sensation. 29 In the past decade, more attention was given to other forms such as aqueous suspension 31 and alcohol-based mouth rinse. 29 The only clinical trial in which orabase form of triamcinolone compares with mouthwash preparation showed similar clinical efficacy but better acceptability for mouthwash.…”

“…29 In the past decade, more attention was given to other forms such as aqueous suspension 31 and alcohol-based mouth rinse. 29 The only clinical trial in which orabase form of triamcinolone compares with mouthwash preparation showed similar clinical efficacy but better acceptability for mouthwash. 29 Regarding safety profile of triamcinolone acetonide paste, we found no adverse event.…”

“…29 The only clinical trial in which orabase form of triamcinolone compares with mouthwash preparation showed similar clinical efficacy but better acceptability for mouthwash. 29 Regarding safety profile of triamcinolone acetonide paste, we found no adverse event. This is similar to a recent study of this agent that found no side effect, but was less than a previous report of 25% (4 of 16) occurrence of candidiasis infection.…”

Glaskörperersatz als Möglichkeit zur protrahierten Freisetzung von Medikamenten im Glaskörper

“…Tano und Machemer befürworteten deshalb schon frühzeitig den Einsatz von Depotpräparaten. Das bekannteste ist Triamcinolon-Acetonid, welches aufgrund seines geringen Löslichkeits-gleichgewichts von 82 µM (36 µg/ml) ein vorteilhaftes pharmakokinetisches Profil besitzt [37]. Die biologische Halbwertszeit beträgt nach Injektion von 4 mg Triamcinolon durchschnittlich 18,6 Tage, woraus sich therapeutisch relevante Konzentrationen über 13 Wochen ableiten lassen.…”